3FDA Stock Overview
Operates as a real estate company in Greece. More details
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 1/6 |
Past Performance | 4/6 |
Financial Health | 2/6 |
Dividends | 3/6 |
Rewards
Risk Analysis
Premia Real Estate Investment Company Societe Anonyme Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €1.17 |
52 Week High | €1.29 |
52 Week Low | €1.08 |
Beta | 1.22 |
11 Month Change | 1.04% |
3 Month Change | -3.79% |
1 Year Change | 3.00% |
33 Year Change | n/a |
5 Year Change | 43.14% |
Change since IPO | -97.23% |
Recent News & Updates
Recent updates
Shareholder Returns
3FDA | DE Real Estate | DE Market | |
---|---|---|---|
7D | 0% | -2.2% | -1.3% |
1Y | 3.0% | 6.4% | 7.4% |
Return vs Industry: 3FDA underperformed the German Real Estate industry which returned 8.1% over the past year.
Return vs Market: 3FDA underperformed the German Market which returned 7.1% over the past year.
Price Volatility
3FDA volatility | |
---|---|
3FDA Average Weekly Movement | 3.0% |
Real Estate Industry Average Movement | 5.6% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.8% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3FDA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 3FDA's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1991 | 16 | Kostas Markazos | www.premia.gr |
Premia Real Estate Investment Company Societe Anonyme operates as a real estate company in Greece. Its portfolio consists of industrial properties, logistics centers, plots, commercial properties, service apartments, and wineries-vineyards, as well as social infrastructure properties, such as schools. The company was formerly known as Premia S.A. and changed its name to Premia Real Estate Investment Company Societe Anonyme in June 2022.
Premia Real Estate Investment Company Societe Anonyme Fundamentals Summary
3FDA fundamental statistics | |
---|---|
Market cap | €100.99m |
Earnings (TTM) | €19.72m |
Revenue (TTM) | €19.62m |
5.1x
P/E Ratio5.1x
P/S RatioIs 3FDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
3FDA income statement (TTM) | |
---|---|
Revenue | €19.62m |
Cost of Revenue | €4.27m |
Gross Profit | €15.35m |
Other Expenses | -€4.37m |
Earnings | €19.72m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.23 |
Gross Margin | 78.24% |
Net Profit Margin | 100.51% |
Debt/Equity Ratio | 128.1% |
How did 3FDA perform over the long term?
See historical performance and comparison